GlassScriptPhysician profile
Cory Jay Alfers
NPI 1063667566
$304.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.14 · 2022: $229.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $46.64 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.79 | 2021-2022 | |
| Lundbeck LLC | $33.28 | 2022 | |
| Abbvie INC. | $25.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.47 | 2022 | |
| Alkermes, INC. | $19.93 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.91 | 2022 | |
| Neos Therapeutics, LP | $18.49 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.41 | 2021 | |
| Bausch Health US, LLC | $12.43 | 2022 | |
| Sage Therapeutics, LLC | $12.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Alfers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.